Mutation in TET2 or TP53 predicts poor survival in patients with myelodysplastic syndrome receiving hypomethylating treatment or stem cell transplantation.
作者信息
Kim M, Yahng S-A, Kwon A, Park J, Jeon Y-W, Yoon J-H, Shin S-H, Lee S-E, Cho B-S, Eom K-S, Lee S, Min C-K, Kim H-J, Cho S-G, Kim D-W, Lee J-W, Min W-S, Lee S-H, Kim Y-J
机构信息
Department of Laboratory Medicine, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Catholic Blood and Marrow Transplantation Center, Seoul St Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
出版信息
Bone Marrow Transplant. 2015 Aug;50(8):1132-4. doi: 10.1038/bmt.2015.110. Epub 2015 May 11.
PMID:25961778
Abstract
摘要
Zotero 插件